protamine zinc

07/01/2009 - "Field safety and efficacy of protamine zinc recombinant human insulin for treatment of diabetes mellitus in cats."
04/01/2009 - "Preliminary study of protamine zinc recombinant insulin for the treatment of diabetes mellitus in cats."
01/01/2021 - "Field efficacy and safety of protamine zinc recombinant human insulin in 276 dogs with diabetes mellitus."
02/01/1975 - "Comparison of injection techniques for soluble and protamine zinc insulins in diabetes mellitus."
04/03/1948 - "Observations on the use of mixtures of protamine zinc and regular insulins in the management of diabetes mellitus."

01/01/2012 - "Efficacy of protamine zinc recombinant human insulin for controlling hyperglycemia in dogs with diabetes mellitus."
06/15/1986 - "Rebound hyperglycemia was observed with both intermediate (neutral protamine hagedorn) and long-acting (protamine zinc iletin) insulins, and the range of insulin doses at which the disorder developed overlapped previously determined therapeutic doses for these insulins in the cat. "
06/01/1946 - "Fasting blood sugar vs. postprandial blood sugar as observed in normal individuals, medical (non-diabetic) patients, and patients with diabetes; special references to; plain, protamine zinc and globin insulins, compatible hyperglycemia and arteriosclerosis."

01/01/2021 - "The hypothesis for this study was that Protamine Zinc Recombinant Human Insulin (PZIR) is safe and efficacious as a once-daily (SID) treatment for canine DM. "

08/01/1980 - "The present studies examined the duration of inhibitory action of a preparation of cyclic somatostatin (SRIF) in suspension with protamine zinc (PZ) on (1) physiologic growth hormone (GH) and immunoreactive insulin (IRI) secretion during feeding in the rat and (2) plasma IRI levels in a 10-year-old boy with idiopathic hyperinsulinemic hypoglycemia. "

12/01/2015 - "Sixty-two newly diagnosed and drug-naïve patients with type 2 diabetes were randomized to exenatide (EXE, n = 20), mixed protamine zinc recombinant human insulin lispro injection (25R; INS, n = 21) or pioglitazone (PIO, n = 21) group for a 24-week treatment. "